Undue industry influence may be compromising the very guidelines that doctors rely on for diagnosing and treating patients. This is because of a legal, but controversial, practice that permits researchers with financial ties to pharmaceutical companies (such as those who participate on company speakers bureaus or who receive large research grants) to serve as experts on medical guideline-writing panels.